EC Number   |
Expression |
Reference |
|---|
    4.4.1.20 | down |
expression in mast cells is not apparent in healthy subjects |
708181 |
| 4.4.1.20 | down |
hepatic mRNA expression of LTC4S is decreased in presence of NO donor O2-vinyl-1-(pyrrolidin-1-yl)-diazen-1-ium-1,2-diolate, i.e. V-PYRRO/NO. Downregulation may occur via inhibiting NF-kappaB activation independent of IkappaBalpha during hepatic ischemia/reperfusion injury |
747243 |
| 4.4.1.20 | down |
no upregulation by interleukin-4 in the THP-1 cell line |
708859 |
| 4.4.1.20 | more |
is not suppressed by pretreatment with the p38 inhibitor |
708600 |
| 4.4.1.20 | up |
LTC4s increases following spared nerve injury, significant increase 3 days after nerve injury and continues at least for 14 days. LTC4s mRNA is expressed constitutively throughout the grey matter and increases after nerve injury in dorsal horn. This increase in LTC4s mRNA mainly occurrs in cells with small nuclei |
708600 |
| 4.4.1.20 | up |
mRNA levels for the three key enzymes/proteins in the biosynthesis of cysteinyl-leukotrienes, 5-lipoxygenase, 5-LO-activating protein, and LTC4 synthase, are significantly increased in the wall of human abdominal aortic aneurysm |
716764 |
| 4.4.1.20 | up |
significantly elevated immunoexpression of LTC4 synthase observed in perennial allergic rhinitis biopsies |
708181 |
